NasdaqCM - Delayed Quote USD

Eupraxia Pharmaceuticals Inc. (EPRX)

Compare
3.0000
-0.0500
(-1.64%)
At close: January 10 at 4:00:00 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
31,500.0880
27,847.2290
17,617.4520
14,648.9286
1,761.4989
Operating Income
-31,500.0880
-27,847.2290
-17,617.4520
-14,648.9286
-1,761.4989
Net Non Operating Interest Income Expense
435.8310
-307.2040
-551.0570
-965.4437
-1,475.2706
Other Income Expense
2,281.1390
-775.1500
-822.2550
-2,714.3998
91.5658
Pretax Income
-28,783.1180
-28,929.5830
-18,990.7640
-18,328.7721
-3,145.2037
Tax Provision
--
36.4230
--
--
--
Net Income Common Stockholders
-28,220.5790
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Diluted NI Available to Com Stockholders
-28,220.5790
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Basic EPS
-0.93
-1.17
-0.96
-1.47
-0.24
Diluted EPS
-0.93
-1.17
-0.96
-1.47
-0.24
Basic Average Shares
31,847.4050
24,146.6230
19,285.4470
12,405.8380
12,865.2730
Diluted Average Shares
31,847.4050
24,146.6230
19,285.4470
12,405.8380
12,865.2730
Rent Expense Supplemental
--
--
--
--
30.9255
Total Expenses
31,500.0880
27,847.2290
17,617.4520
14,648.9286
1,761.4989
Net Income from Continuing & Discontinued Operation
-28,220.5790
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Normalized Income
-30,501.7180
-27,755.7060
-17,667.3740
-17,089.2762
-3,226.2328
Interest Income
1,295.7270
862.9690
431.7990
51.5506
0.3349
Interest Expense
859.8960
1,170.1730
982.8560
1,016.9942
1,475.6054
Net Interest Income
435.8310
-307.2040
-551.0570
-965.4437
-1,475.2706
EBIT
-27,923.2220
-27,759.4100
-18,007.9080
-17,311.7779
-1,669.5983
EBITDA
-27,764.7820
-27,603.8830
-17,860.0140
-17,224.3055
-1,577.9949
Reconciled Depreciation
158.4400
155.5270
147.8940
87.4724
91.6034
Net Income from Continuing Operation Net Minority Interest
-28,220.5790
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Total Unusual Items Excluding Goodwill
2,281.1390
-775.1500
-822.2550
-941.5044
91.5658
Total Unusual Items
2,281.1390
-775.1500
-822.2550
-941.5044
91.5658
Normalized EBITDA
-30,045.9210
-26,828.7330
-17,037.7590
-16,282.8011
-1,669.5607
Tax Rate for Calcs
--
0.0004
--
--
--
Tax Effect of Unusual Items
--
-310.0600
--
--
--
12/31/2020 - 4/5/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FENC Fennec Pharmaceuticals Inc.
5.91
-2.80%
 
NGENF NervGen Pharma Corp.
2.1250
+0.24%
 
MSCL.TO Satellos Bioscience Inc.
0.8500
+1.19%
 
NGEN.V NervGen Pharma Corp.
3.0900
+3.69%
 
ACOG Alpha Cognition Inc.
6.10
+6.56%
 
MSCLF Satellos Bioscience Inc.
0.5990
0.00%
 
PSTV Plus Therapeutics, Inc.
1.1600
-3.33%
 
CWBR CohBar, Inc.
0.4100
0.00%
 
GNFT Genfit S.A.
3.6000
0.00%
 
CSBR Champions Oncology, Inc.
9.47
-1.97%